Pharvaris to Showcase Novel Oral HAE Treatments at Upcoming Congresses

Pharvaris announces abstracts accepted for presentation at three upcoming congresses, showcasing novel oral bradykinin B2 receptor antagonists for treating hereditary angioedema attacks. Presentations will take place at IDDST, EAC, and EAACI congresses in May and June 2024.

author-image
Nitish Verma
New Update
Pharvaris to Showcase Novel Oral HAE Treatments at Upcoming Congresses

Pharvaris to Showcase Novel Oral HAE Treatments at Upcoming Congresses

Pharvaris N.V., a late-stage biopharmaceutical company, announced on May 13, 2024, that it has had abstracts accepted for presentation at three upcoming congresses: the 20th Annual Congress of International Drug Discovery Science and Technology (IDDST), the 2024 Eastern Allergy Conference (EAC), and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024. The presentations will showcase the company's novel, oral bradykinin B2 receptor antagonists for treating and preventing hereditary angioedema (HAE) attacks.

Why this matters: The development of novel treatments for hereditary angioedema (HAE) has the potential to significantly improve the quality of life for individuals affected by this rare genetic disorder. Effective management of HAE attacks can also reduce the risk of life-threatening complications and alleviate the burden on healthcare systems.

The IDDST 2024 will take place from May 22-24, 2024, in Osaka, Japan. The EAC 2024 is scheduled for May 30-June 2, 2024, in Palm Beach, Florida, U.S. The EAACI Congress 2024 will be held from May 31-June 3, 2024, in Valencia, Spain. The abstracts from the EAACI Congress will be published in Allergy, the European Journal of Allergy and Clinical Immunology, after the Congress. Pharvaris will make the posters and presentation slides available on the Investors section of its website at the beginning of the respective presentation sessions.

Pharvaris, headquartered in Zug, Switzerland, is a Nasdaq-listed company (PHVS) with deep expertise in rare diseases and HAE. The company's mission is to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically.

HAE is a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body, including the airways, which can be life-threatening. The condition is caused by a deficiency or dysfunction of the C1 esterase inhibitor protein, leading to excessive production of bradykinin, a peptide that causes blood vessels to leak fluid into surrounding tissues.

Pharvaris' novel oral bradykinin B2 receptor antagonists aim to address the unmet needs in HAE treatment by providing a convenient and effective option for patients to manage their condition. The upcoming presentations at the IDDST, EAC, and EAACI congresses will highlight the potential of these innovative therapies in improving the lives of individuals affected by HAE.

Key Takeaways

  • Pharvaris to present at 3 congresses: IDDST, EAC, and EAACI.
  • Presentation topics: novel oral bradykinin B2 receptor antagonists for HAE.
  • HAE is a rare genetic disorder causing recurring severe swelling episodes.
  • New treatments can improve quality of life and reduce healthcare burden.
  • Pharvaris aims to provide convenient and effective HAE management options.